vimarsana.com

Latest Breaking News On - Attestation engagements - Page 8 : vimarsana.com

Pango Group Passes Its SSAE 18 Type II Audit for Sixth Consecutive Year

Pango Group Passes Its SSAE 18 Type II Audit for Sixth Consecutive Year News provided by Share this article Share this article GLENDALE, Calif., Dec. 17, 2020 /PRNewswire/ Pango Group recently announced that it has successfully completed a Statement on Standards for Attestation Engagements No. 18 (SSAE 18) SOC 1 & SOC 2 Type II audit for its sixth consecutive year. With the ever-evolving regulations mandated by the Consumer Financial Protection Bureau (CFPB), Pango Group is proud to be one of the first independent escrow companies in California to complete this Type II audit. By establishing and implementing systems that meet the guidelines of ALTA Best Practices and Escrow Institute Model Policies and Procedures, Pango Group is in the best position to be compliant with many of the lender requirements due to the CFPB regulations.

Renalogic Completes Service Organization Controls 2 (SOC 2) Report under AT-C Section 205 – IT Business Net

PHOENIX–(BUSINESS WIRE)–#chronickidneydiseasemanagement–Renalogic, an industry leader in dialysis risk management and cost containment, announced that it has completed its Service Organization Controls 2 (SOC 2) examination under the Statement on Standards for Attestation Engagements No. 18 (AT-C section 205, Examination Engagements) of the AICPA that was performed by an independent auditing firm. Completion of the SOC 2 Type II examination indicates that selected Renalogic processes, procedures, and controls have been formally evaluated and tested by an independent accounting and auditing firm. The examination included the company’s controls related to the 2017 Trust Services Principles and Criteria for Security and Privacy. For more than a decade, Renalogic has been using data to mitigate chronic kidney disease (CKD) and dialysis risk for health plans and their members. Last month, Renalogic introduced CareINSIGHTS.ai as the company’s next evolution of intervention p

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.